Partnership for Research on Ebola VACCination

Pr Yazdan Yazdanpanah
PREVAC

- Evaluation of safety and immunogenicity of 3 Ebola vaccine strategies in children above 1 and adults
- Phase IIB
- Randomised
- Double-blind
- Placebo controlled
- Multicentre in Guinea, Liberia, Mali, Sierra Leone
PREVAC Consortium members

Liberia
Dr Kennedy / Dr Kieh

Mali
Pr Sow / Dr Doumbia

Guinea
Dr Beavogui

Sierra-Leone
Pr Leigh

Anthropologist Team

Inserm

Inserm / euclid
F-CRRN platform for clinical trials

University of Minnesota
Driven to Discover℠

MERCK

janssen

BAVARIAN NORDIC
PREVAC Timelines

PREVAC/PREVAC-UP large scale clinical trial including long term follow-up

- Inclusion of participants in preliminary phases
- Inclusion period PREVAC latest version of protocol

Follow-up
Immunological studies
Co-infection studies
System Vaccinology modeling
Social sciences research
Capacity building - Training

PREVAC activities
funded by NIAID, Inserm, LEIDOS, IMI2 JU

PREVAC-UP strategic action
expected funds from EDCTP2
co-funded by NIAID, Inserm and LSHTM
In Total: 4,789 participants randomized in all PREVAC phases

- 2,560 Adults
- 2,229 Children (1 to 17 years old)
After protocol finalization

**TSC**
Trial Steering Committee

**DSMB**
Data Safety and Monitoring Board

**TMT**
Trial Management Team

**Investigator Coordinator Team**

**Governance**

**DM & Statistical Team**

- **National TMT Liberia**
  - Participating sites & on-site operational teams Liberia

- **National TMT Guinea**
  - Participating sites & on-site operational teams Guinea

- **National TMT Sierra-Leone**
  - Participating sites & on-site operational teams Sierra-Leone
Funding/Acknowledgments

• This research was supported in part by the National Institutes of Health (NIH), by Institut national de la santé et de la recherche médicale (Inserm) and by the London School of Hygiene and Tropical Medicine (LSHTM).
• The clinical trial was conducted with the support of Janssen, Bavarian Nordic and Merck Sharp & Dohme Corp. who provided the vaccines according to EBOVAC 1 grant agreement.
• This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115854, EBOVAC1. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The dissemination represents only the authors’ views and IMI2JU is not responsible for any use of the information contained in the dissemination.
• Funding provided in part by NCI contract HHSN261201500003I through the Frederick National Laboratory for Cancer Research.
• The project has been funded by a dedicated Inserm allocation on behalf the Minister of Higher Education, Research and Innovation.
• This project is part of the EDCTP2 programme supported by the European Union and by the US National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
• We are grateful to the Ministries of Health of Guinea, Liberia, Sierra Leone and Mali who permitted the conduct of the trial.
• We furthermore thank Alima and all site collaborators for their contribution in the implementation of the trial.
• The authors and study team wish to thank the participants who consented to the trial.
Acknowledgments

PREVAC Study team